Lau Antony K, Leichtweis Steven B, Hume Peter, Mashima Ryuichi, Hou Jing Y, Chaufour Xavier, Wilkinson Barbara, Hunt Nicholas H, Celermajer David S, Stocker Roland
The Heart Research Institute, Sydney, Australia.
Circulation. 2003 Apr 22;107(15):2031-6. doi: 10.1161/01.CIR.0000062682.40051.43. Epub 2003 Apr 7.
Probucol remains the only conventional drug that reduces restenosis after coronary angioplasty. Apart from its weak cholesterol-lowering effect, probucol has antioxidant properties, but it remains unclear how this drug inhibits restenosis.
Aortic balloon-injured New Zealand White rabbits were fed 2% (wt/wt) cholesterol-enriched or normal chow, with 0.75% (wt/wt) probucol (P) or without (controls, C) for 6 weeks. Endothelial denudation of the abdominal aorta was performed at week 3 with a 3F Fogarty embolectomy catheter. The arteries were harvested after week 6 and analyzed for histology, lipids and antioxidants, and endothelial regeneration and function. Probucol significantly decreased aortic intima-to-media ratio (cholesterol-fed: C, 1.10+/-0.08 versus P, 0.70+/-0.10; normal: C, 0.89+/-0.02 versus P, 0.83+/-0.05; P<0.05) and the numbers of proliferating intimal smooth muscle cells and lowered serum cholesterol without altering the proportion of aortic lipids that was oxidized. Probucol promoted endothelial regeneration in the injured aorta in cholesterol-fed rabbits (25% increase in reendothelialization, P<0.05) and in those on normal chow (37% increase, P<0.01). This was associated with both improved endothelial function as assessed by enhanced aortic ring relaxation and cGMP production in response to acetylcholine and decreased intimal thickening.
Probucol inhibits intimal thickening in balloon-damaged arteries of rabbits by promoting the regeneration of functional endothelium, without affecting the proportion of aortic lipids that was oxidized. This novel in vivo finding helps explain how probucol inhibits restenosis after coronary angioplasty and highlights potential new targets for therapeutic intervention.
普罗布考仍然是唯一一种能降低冠状动脉血管成形术后再狭窄的传统药物。除了其微弱的降胆固醇作用外,普罗布考还具有抗氧化特性,但该药物如何抑制再狭窄仍不清楚。
给新西兰白兔的腹主动脉造成气囊损伤,然后将其分为两组,一组喂食含2%(重量/重量)胆固醇的饲料或正常饲料,同时添加0.75%(重量/重量)普罗布考(P组),另一组不添加普罗布考(对照组,C组),持续6周。在第3周时,使用3F Fogarty取栓导管对腹主动脉进行内皮剥脱。第6周后采集动脉,进行组织学、脂质和抗氧化剂分析,以及内皮再生和功能分析。普罗布考显著降低了主动脉内膜与中膜的比例(喂食胆固醇组:C组为1.10±0.08,P组为0.70±0.10;正常饲料组:C组为0.89±0.02,P组为0.83±0.05;P<0.05),减少了内膜增殖平滑肌细胞的数量,并降低了血清胆固醇水平,同时未改变主动脉脂质氧化的比例。普罗布考促进了喂食胆固醇的兔子(再内皮化增加25%,P<0.05)和喂食正常饲料的兔子(再内皮化增加37%,P<0.01)损伤主动脉的内皮再生。这与通过增强主动脉环舒张以及对乙酰胆碱反应时的cGMP产生所评估的内皮功能改善和内膜增厚减少相关。
普罗布考通过促进功能性内皮的再生来抑制兔气囊损伤动脉的内膜增厚,而不影响主动脉脂质氧化的比例。这一在体内的新发现有助于解释普罗布考如何抑制冠状动脉血管成形术后的再狭窄,并突出了治疗干预的潜在新靶点。